FDA Commissioner Marty Makary said his agency plans to release a new framework for vaccine approvals in “coming days.” ...

A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations ...

Pfizer will continue operating in Lee County after consolidating facilities. The move comes 18 months after Pfizer confirmed ...

The European Court of Justice Wednesday ruled there was no plausible reason to block the New York Times from getting European ...

A top European court says the European Commission failed to provide a credible explanation for refusing The New York Times ...

After 6 months, placebo was associated with a mean weight gain of 0.4 kg (o.88 lb), compared with 1.2-1.9 kg (2.6-4.2 lb) ...

China said on Wednesday it would further enhance capital market support for science and technology innovation enterprises and ...

Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...

Pfizer (PFE) stock draws public scrutiny as a House probe gathers new allegations regarding the company's COVID-19 vaccine ...

Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...

The federal judge’s ruling has nothing to do with the merits of Kobach’s scientifically dubious argument that the vaccine isn’t as safe or effective as Pfizer advertised.

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.